

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GUT et al.

Title: METHOD FOR HLA TYPING

Appl. No.: Unassigned (US National Stage of PCT/IB2004/004115)

International 11/26/2004

Filing Date:

371(c) Date:

Examiner: Unassigned

Art Unit: Unassigned

Confirmation Unassigned

Number:

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

10/580646

IAP9 Rec'd PCT/PTO 25 MAY 2006

Atty. Dkt. No. 065691-0447

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

RELEVANCE OF EACH DOCUMENT

The documents being cited in the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding international application. A copy of the International Search Report is attached setting forth the portion of the documents considered relevant by the examiner. Copies of the cited references listed in the Search Report are not being submitted herewith.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Stephen B. Maebius
By Reg. No. 32,904, Jr.

Date May 25, 2006

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

~~U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE~~
~~100 Rainey Street, Stop 25 MAY 2006~~

Substitute for form 1449B/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
Date Submitted: May 25, 2006					
(use as many sheets as necessary)					
Sheet	1	of	1	Attorney Docket Number	065691-0447

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
A1	5,451,512	A	APPLE et al.		09/19/1995	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A2	WO	00/65088	A	Amersham Pharm. Biotech. AB	11/02/2000		
	A3	WO	02/08462	A	Lechner et al.	01/31/2002		
	A4	WO	02/18659	A	Haplogen LLC	03/07/2002		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A5	PASTINEN et al., "Multiplex, fluorescent, solid-phase minisequencing for efficient screening of DNA sequence variation," Clinical Chemistry, American Association for Clinical Chemistry, vol. 42, no. 9, 1996, pp. 1391-1397.	
	A6	WORRALL et al., "Allele-specific HLA-DR typing by mass spectrometry: an alternative to hybridization-based typing methods," Analytical Chemistry, November 1, 2000, vol. 72, no. 21, pp. 5233-5238.	
	A7	LEUSHNER et al., "Automated mass spectroscopic platform for high throughput DR Beta typing," Human Immunology, vol. 61, no. Supplement 2, 2000, p. S126.	
	A8	TOST et al., "Genotyping single nucleotide polymorphisms by mass spectrometry," Mass Spectrometry Reviews, vol. 21, no. 6, November 2002, pp. 388-418.	
	A9	TOST et al., "Molecular haplotyping at high throughput," Nucleic Acids Research, October 1, 2002, vol. 30, n o. 19, p. e96.	
	A10	SAUER et al., "Extension of the good assay for genotyping single nucleotide polymorphisms by matrix-assisted laser desorption/ionization mass spectrometry," Rapid Communications in Mass Spectrometry, vol. 17, no. 12, May 9, 2003, pp. 1265-1272.	
	A11	SAUER et al., "Genotyping single-nucleotide polymorphisms by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry," Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, December 25, 2002, vol. 782, no. 1-2, pp. 73-87.	
	A12	ROZEMULLER, "Reference panels for sequence based typing: Selection criteria for HLA-A and HLA-B," 2000, retrieved from the Internet: URL: http://www.ihwg.org/tmanual/TMcontents.htm , retrieved on 07/05/2004.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.